Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series

BACKGROUND: National treatment guidelines recommend glucagon-like peptide receptor agonists (GLP-1 RAs) as add-on therapy to oral agents. However, GLP-1 RAs in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors is not recommended due to a lack of evidence. OBJECTIVE: This case series aims to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lajthia, Estela, Bucheit, John D., Nadpara, Pramit A., Dixon, Dave L., Caldas, Lauren M., Murchie, Michael, Sisson, Evan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935552/
https://www.ncbi.nlm.nih.gov/pubmed/31897252
http://dx.doi.org/10.18549/PharmPract.2019.4.1588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935552/
https://www.ncbi.nlm.nih.gov/pubmed/31897252
http://dx.doi.org/10.18549/PharmPract.2019.4.1588

Ejemplares similares